Buzz: Shire gambit reignites rumors of a potential takeover

Shire ($SHPG) has stirred up longtime rumors of a potential takeover attempt after hiring the investment bank Lazard as an adviser. The Sunday Times reported that a bid may be brewing for Shire, which has won kudos for its drug portfolio as well as a busy set of pipeline projects. Most recently Bristol-Myers Squibb ($BMY) was reportedly interested in a buyout. Under new CEO Flemming Ornskov, Shire has been buying up small drug developers, with an eye to grabbing some more rare disease drugs ahead. Story | More from FiercePharma

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.